Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Systemic sclerosis. A vascular perspective

E C LeRoy1

  • 1Department of Microbiology and Immunology Medical University of South Carolina, Charleston 29425, USA.

Rheumatic Diseases Clinics of North America
|November 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association between polymorphic variation in VDR and RXRA and circulating levels of vitamin D metabolites.

The Journal of steroid biochemistry and molecular biology·2010
Same author

The 72-kilodalton IE-1 protein of human cytomegalovirus (HCMV) is a potent inducer of connective tissue growth factor (CTGF) in human dermal fibroblasts.

Clinical and experimental rheumatology·2004
Same author

A profibrotic polymorphism (of TGFbeta1) in systemic sclerosis.

Annals of the rheumatic diseases·2002
Same author

Anti-fibrillin-1 autoantibodies in systemic sclerosis are GM and KM allotype-restricted.

Experimental and clinical immunogenetics·2001
Same author

MCMV induces neointima in IFN-gammaR-/- mice: intimal cell apoptosis and persistent proliferation of myofibroblasts.

BMC musculoskeletal disorders·2001
Same author

Criteria for the classification of early systemic sclerosis.

The Journal of rheumatology·2001
Same journal

Bridging the Divide in Global Rheumatology.

Rheumatic diseases clinics of North America·2026
Same journal

Foreword.

Rheumatic diseases clinics of North America·2026
Same journal

Pulmonary Complications of Biological Therapies in Inflammatory and Autoimmune Diseases.

Rheumatic diseases clinics of North America·2026
Same journal

Artificial Intelligence and Social Determinants of Health.

Rheumatic diseases clinics of North America·2026
Same journal

Updates in Ultrasound in Rheumatology.

Rheumatic diseases clinics of North America·2026
Same journal

Health Systems Strengthening to Promote Access to Care for Rheumatic and Musculoskeletal Diseases Globally.

Rheumatic diseases clinics of North America·2026
See all related articles

The future for scleroderma (SSc) patients is optimistic, with new vascular markers and therapies improving management. Understanding cytokine pathways offers a biologic foundation for treating SSc vascular disease.

Area of Science:

  • Vascular biology
  • Immunology
  • Rheumatology

Background:

  • Scleroderma (SSc) involves complex vascular pathogenesis.
  • Cytokine abnormalities (TGF-beta 1, PDGF) are known contributors.
  • Vascular insufficiency can lead to vital organ failure in SSc.

Purpose of the Study:

  • To highlight the optimistic future for SSc management in a vascular context.
  • To emphasize the role of new surrogate markers and cytokines in understanding SSc.
  • To discuss the potential of combination therapies for preventing organ damage.

Main Methods:

  • Routine use of surrogate markers in patient management.
  • Study of novel cytokines like Vascular Endothelial Growth Factor (VEGF).
  • Analysis of known cytokine cascade abnormalities (TGF-beta 1, PDGF).

Related Experiment Videos

Main Results:

  • New surrogate markers are available for routine clinical use.
  • VEGF and other cytokines provide integrated insights into SSc vascular pathogenesis.
  • Combination therapies can be implemented to prevent critical organ damage.

Conclusions:

  • The outlook for SSc patients and research is positive due to a strong biologic foundation.
  • Advances in understanding vascular mechanisms offer new therapeutic avenues.
  • Despite funding challenges, progress in SSc vascular disease management is significant.